


## RESEARCH ARTICLE

BENTHAM  
SCIENCE

# An Expedient Synthesis of CMF-019: (S)-5-Methyl-3-{1-(pentan-3-yl)-2-(thiophen-2-ylmethyl)-1*H*-benzo[d]imidazole-5-carboxamido}hexanoic Acid, a Potent Apelin Receptor (APJ) Agonist



Lena Trifonov<sup>1</sup>, Michal Afri<sup>1</sup>, Krzysztof Palczewski<sup>2</sup>, Edward E. Korshin<sup>1,\*</sup> and Arie Gruzman<sup>1,\*</sup>

<sup>1</sup>Department of Chemistry, Bar-Ilan University, Ramat-Gan, 5290002, Israel; <sup>2</sup>Department of Pharmacology, School of Medicine, Case Western Reserve University, Cleveland, OH, 44106-4965, USA

**Abstract: Background:** Apelin receptor (APJ) is a G protein-coupled receptor (GPCR) activated by the endogenous peptide apelin. The apelin-APJ system has emerged as an important regulator of cardiovascular homeostasis. Recently, a potent benzimidazole-derived apelin peptidomimetic, CMF-019, was patented but without a comprehensive description of its synthesis and a complete spectroscopic characterization of the intermediates.

**Objective:** Here, a detailed preparation of CMF-019 through a modified and improved synthetic pathway is described.

**Method:** In particular, the benzimidazole ring in **7** was tailored by the condensation of methyl 3-amino-4-(pentan-3-ylamino)benzoate (**4**) with (thiophene-2-yl)acetimidate salt **6**. Saponification of **7** and the subsequent condensation of the free acid **8** with the corresponding enantiopure  $\beta$ -amino acid methyl ester generated methyl (S)-5-methyl-3-{1-(pentan-3-yl)-2-(thiophen-2-ylmethyl)-1*H*-benzo[d]imidazole-5-carboxamido}hexanoate (**9**). Hydrolysis of the latter with KOH in THF/water, followed by HPLC-purification, afforded the desired product, CMF-019 (potassium salt) **10**.

**Results & Conclusion:** The approach reported herein enables preparation of **10** at a total yield of 12% over seven linear steps. Additionally, it does not require applying expensive designated microwave reactors and high-pressure hydrogenators. Thus, the elaborate synthesis provides a latent availability of potent agonist **10** for further exploring the physiologically essential apelin-APJ system.

**Keywords:** CMF-019, peptidomimetics, apelin, apelin receptor, expedient synthesis, benzimidazole scaffold.


## 1. INTRODUCTION

APJ was identified in 1993; [1] it displays the classic structure associated with GPCRs [1]. Apelin, the endogenous peptidic agonist of APJ, was discovered in 1998 by K. Tate-moto *et al.* [2]. The expression pattern of apelin correlates with the localization of the receptor in many human tissues [3]. On the other hand, apelin is also expressed in cells such as adipocytes, which lack the APJ receptor, and it has been detected in plasma at “hormone”-like levels [3]. These data support the hypothesis that apelin might act as a humoral regulator of numerous body functions including cardiovascular homeostasis [4]. A number of mechanisms beneficial to the cardiovascular system, which might be modulated by APJ, have been proposed: positive inotropy, angiogenesis,

reduction of the mean arterial blood pressure, vasodilation by releasing nitric oxide, and blocking of cardiomyocyte apoptosis [4-6]. The potential therapeutic impact from using APJ as a target for the treatment of cardiovascular diseases might be very high. However, along with its scant availability from natural sources, apelin peptides are pharmacokinetically labile and are rapidly metabolized in vivo (half-life *ca.* 5 min) [7]. Thus, designing metabolically stable small-molecule agonists and antagonists for modulating the ARJ system is urgently needed.

Development of apelin like non-peptidic receptor modulators (peptidomimetics) is one of such options. In general, medicinal chemists use this approach (peptidomimetics development) very often [8]. In contrast to peptides, peptidomimetics can induce the desired biological effects without the disadvantages associated with peptides [9]. Recently, Sanofi-Aventis patented a set of small peptidomimetic agonists of APJ, including CMF-019 (compound number 107 in the original patent) as one of the most potent agonists [10].

\*Address correspondence to this author at the Department of Chemistry, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Tel: 972-(0)3-7384597; Fax: 972-(0)3-5351250; E-mail: [gruzmaa@biu.ac.il](mailto:gruzmaa@biu.ac.il)



**Scheme 1.** Synthesis of CMF-019 (potassium salt) **10**: a) MeOH, conc.  $\text{H}_2\text{SO}_4$  (cat.), reflux, 3 h, 91%; b) 3-aminopentane,  $\text{K}_2\text{CO}_3$ , dry THF, room temperature, 4 h, 92%; c) 10% Pd/C,  $\text{H}_2$  (5 bar), EtOH, overnight, 85%; d) AcCl, dry MeOH, dry  $\text{Et}_2\text{O}$ , 0 °C, 1 h, then at 4 °C, 3 days, 87%; e) **4** and **6**, dry MeOH, reflux, 8 h, 57%; f) aq. 1M NaOH, MeOH, THF, room temperature, overnight, 87%; g) methyl (S)-5-methyl 3-aminohexanoate, HOBt, EDC, DIEA, dry DMF, room temperature, 3 days, 58%; h) aq. KOH, THF, at 0 °C, then room temperature, 21 h, 57%.

CMF-019 exhibited impressive biological effects on the cardiovascular system via activation of APJ [11]. The availability of active peptidomimetic APJ-agonists such as CMF-019 could be helpful for elucidating vital physiological processes associated with an apelinergic signalling system. Currently, employment of APJ agonists as positive modulators of the cardiovascular system is under intense study and it has begun to attract the increasing attention of the scientific community. However, the earlier reported syntheses of CMF-019 and related compounds lack a detailed description of the experimental procedures and a spectroscopic characterization of the intermediates [10, 11]. Here, we unveil all the relevant details of the experimentally simplified and improved synthesis of CMF-019 (potassium salt), which largely follows the route briefly described by Read *et al.* [11]. We believe

that the availability of reliable and reasonably yielding CMF-019 synthesis can be helpful towards clarifying the role of the apelin-APJ system in cardiovascular homeostasis and other vital physiological processes.

## 2. RESULTS AND DISCUSSION

The expedient synthesis of CMF-019 is shown in Scheme 1. In the first step, esterification of commercially available acid **1** with methanol and a catalytic amount of concentrated  $\text{H}_2\text{SO}_4$ , following a slightly modified reported procedure, [12] provided crude NMR-pure ester **2** at 91% yield. Treatment of crude **2** with 3-aminopentane in the presence of  $\text{K}_2\text{CO}_3$  in dry THF resulted in the efficient nucleophilic aromatic substitution of fluorine, affording aromatic secondary

amine **3** (92%), which was found to be NMR-pure in a crude state. In our hands, the original procedure using DMF as a solvent [10] afforded a more complex reaction mixture that necessitated the tedious isolation of **3** [ $<80\%$  yield after sequential flash chromatography (FC)]. According to the original procedure, the next high-yielding reduction of the nitro group in **3** to afford N-monosubstituted *ortho*-phenylenediamine **4** required 4 h of catalytic hydrogenation at 15 bar hydrogen pressure [10]. Since we are limited in high-pressure hydrogenation equipment, we successfully converted the crude nitroaniline **3** into phenylenediamine **4** (85% after FC purification) after 16 h of hydrogenation over 10% Pd/C catalyst (1.4 mol-% Pd loading) in ethanol under 5 bar hydrogen pressure in a regular Parr machine. Under these experimental conditions, a shortening of hydrogenation time to 4 h repeatedly led to the incomplete reduction and inferior yields of the intermediate **4** (60–64%). Nevertheless, a 4-time elongation of the hydrogenation time successfully compensated for a 3-time lowering of the hydrogen pressure.

In the original approach, preparation of benzimidazole **7** relied on the acylation of **4** with 2-thiopheneacetyl chloride, followed by cyclization of the resulting amide in acetic acid at 140 °C under microwave irradiation [10, 11]. However, all attempts to accomplish such cyclization using a domestic microwave oven that was available in our lab were largely unsuccessful ( $<10\%$  yield of **7** in the cyclization step). Perhaps the reported procedure [10, 11] could be reproduced by using scientific microwave reactors only [13]. Since our lab, like many other synthetic and medicinal chemistry laboratories, especially in developing countries, still lacks such an attractive, but rather expensive dedicated equipment, the microwave reactor-dependent step was replaced by a regular organic reaction. The direct cyclization of N-substituted *ortho*-phenylenediamine **4** with methyl 2-thiophenacetimidate hydrochloride **6** [14] was adopted. Indeed, iminoester salts are widely applied as one-carbon electrophiles and are generally more active than are carboxylic acids, in cyclizations with N-unsubstituted *ortho*-phenylenediamines affording N-unsubstituted benzimidazoles [15]. However, the set of non-patented examples describing the condensation of imidate salts with N-substituted *ortho*-phenylenediamines to afford the corresponding N-substituted benzimidazoles is minimal, varying considerably in both synthetic viabilities and in the reaction conditions [16]. In the current study, imidate hydrochloride **6** was synthesized at 87% yield, according to a further development of a “modified Pinner method” [17] from commercially available 2-thiophene acetonitrile (**5**), methanol, and acetyl chloride in dry ether at 0 °C. The hydrolytically labile crystalline imidate salt **6** was precipitated directly from the reaction mixture, which significantly simplified its isolation. Subsequent reflux of N-alkyl-substituted *ortho*-phenylenediamine **4** and imidate hydrochloride **6** in dry methanol for 8 h led to the condensation of the reactants, affording the desired 5-carbomethoxybenzimidazole **7** (57%). Although the overall yields of benzimidazole **7** from **4** in the previously reported [10, 11] and in our approach are comparable, the reported herein “microwave-free” method could be more practical for many scientific teams dealing with synthesis.

From a mechanistic viewpoint, condensation of imidate salt **6** with *ortho*-phenylenediamine **4**, producing benzimidazole **7**, consists of two single steps: (i) slow intermolecular aminolysis of **6** by **4** and replacing the alkoxy-group by a more nucleophilic ArNH<sub>2</sub>-group and the formation of an unstable N-(2-alkylaminophenyl)amidinium-type intermediate; [18] and (ii) the subsequent rapid intramolecular aminolysis of the positively charged amidinium system by the neighbouring alkylaryl-amino-group, resulting in benzimidazole **7** ring closure [19].

Basic hydrolysis of methyl ester **7**, followed by acidification, afforded the free acid **8** in good yield [10]. The chiral  $\beta$ -amino ester residue was attached to the free carboxylic group of **8** by HOBt, and EDC induced condensation with commercially available enantiopure methyl (*S*)-3-amino-5-methyl hexanoate [20] in dry DMF. A pure direct precursor, **9**, was isolated at 58% yield after FC on a softly basic Florisil absorbent. In contrast, FC on a slightly acidic silica gel led to considerable decomposition of product **9**. This observation supports the conclusion that low yields of  $\beta$ -amidoacid CMF-019 (*ca.* 20%), obtained by the previously described condensation of **8** with (*S*)-3-amino-5-methylhexanoic acid, [10, 11] could have resulted from the inherent lability of the acidic form of CMF-019 rather than from insufficiency of the condensation process itself.

In the final step of the synthesis, deprotection of methyl ester **9** by directly converting to the potassium salt of CMF-019 (**10**) was accomplished. Formation of salt **10** probably improves the stability of CMF-019. Furthermore, the salt from **10** is critical for the compound's solubility in water and for its administration either to cells growing in medium or to animals [11]. Initially, we attempted to convert ester **9** to the potassium salt of CMF-019 (**10**) using purified potassium trimethylsilanolate, which is widely recognized as a superior reagent for conversion of methyl esters to potassium salts of the corresponding carboxylic acids [21]. However, our continuous experiments with Me<sub>3</sub>SiOK in dry THF or ether gave insufficient yields of **10** (20–30%). To our delight, ester **9** simply treated with KOH in THF/water, followed by reverse-phase HPLC-purification, afforded the desired product, CMF-019 (potassium salt) (**10**) (57% yield), as a hygroscopic colorless solid. In summary, the procedures reported here expedite the synthesis of CMF-019 (potassium salt) (**10**) to a total of 12% yield following seven linear steps.

### 3. MATERIALS AND METHODS

<sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded at ambient temperatures at 400 and 100 MHz, respectively, using a Bruker Avance-400 NMR spectrometer, or at 700 and 175 MHz, respectively, using Bruker Avance-700 NMR spectrometer. The chemical shifts are reported in ppm units ( $\delta$ ) relative to TMS at 0 ppm. The residual hydrogen signals of the deuterated solvents ( $\delta_{\text{H}} = 7.26$  ppm in CDCl<sub>3</sub>, 7.16 ppm in C<sub>6</sub>D<sub>6</sub>, and 2.50 ppm in DMSO-*d*<sup>6</sup>) were used as internal references in the <sup>1</sup>H NMR measurements [22]. In the <sup>13</sup>C NMR measurements, the chemical shifts were referenced to the signals of CDCl<sub>3</sub> ( $\delta_{\text{C}} = 77.1$  ppm), C<sub>6</sub>D<sub>6</sub> (128.0 ppm) and DMSO-*d*<sup>6</sup> (39.5 ppm) [22]. Coupling constants, *J*, are reported in Hertz. All the given assignments are based on a

combination of 1D ( $^1\text{H}$  and  $^{13}\text{C}/\text{DEPT}$ ) and 2D (COSY, HMQC, and HMBC) NMR spectra. The splitting pattern and the assignment abbreviations are as follows: s, singlet; d, doublet; t, triplet; q, quartet; qui, quintet; m, unresolved multiplet; br., broad; BZM, benzimidazole; and Th, thiophene.

High-resolution mass spectra (HRMS) were obtained using a QTOF instrument (Agilent) or an LTQ Orbitrap XL (Thermo Scientific) mass spectrometer in electrospray ionization (ESI) mode. The specific light rotation was measured with a JASCO digital polarimeter (Model P-1010  $\lambda = 589$  nm,  $\pm 0.05^\circ$  accuracy) using a cylindrical quartz cell (5 mL,  $L = 5$  cm) at room temperature by dissolving the crystals in  $\text{CHCl}_3$ . Melting points were measured with a Fisher-Johns melting point apparatus and are uncorrected. Column flash chromatography (FC) was performed on silica gel 60 (230–400 mesh ASTM) from Merck or on Florisil (100–200 mesh) from Fluka. Analytical TLC was carried out on pre-coated Silica gel 60F<sub>254</sub> (Merck) sheets using UV illumination and charring with vanillin stain for visualization. Preparative HPLC-separation was performed with an HPLC column (Luna 10-micron C18(2) 100A AX 100X30.00 mm 10 micron), using a  $\text{H}_2\text{O}/\text{MeCN}$  gradient system of solvents: (i) 0–20 min [100/0]; (ii) gradient of 20 min [100/0] – 100 min [0/100]. The flow rate was 5 mL/min.

Dry THF was prepared by refluxing over sodium/benzophenone ketyl, followed by distillation under nitrogen. Other commercially available reagents and solvents were purchased and used as received.

## 4. EXPERIMENTAL

### 4.1. Synthetic Procedures

#### 4.1.1. Methyl 4-fluoro-3-nitrobenzoate (2) [12]

4-Fluoro-3-nitrobenzoic acid (5.55 g, 29.98 mmol) was dissolved in methanol (50 mL) and concentrated  $\text{H}_2\text{SO}_4$  (6.40 mL) was added. The reaction mixture was refluxed for 3 h with protection from atmospheric moisture. The reaction mixture was cooled to ambient temperature and poured into crushed ice. The precipitated colorless solid was collected by suction, thoroughly washed with water, and dried in vacuum to afford 5.49 g (91%) of the NMR-pure ester **2**.  $^1\text{H}$ ,  $^{13}\text{C}/\text{DEPT}$  NMR spectra, and m.p. of the prepared **2** completely match the reported data [12].

#### 4.1.2. Methyl 3-nitro-4-(pentan-3-ylamino)benzoate (3)

To a mixture of methyl 4-fluoro-3-nitrobenzoate (**2**) (5.0 g, 25.3 mmol) and  $\text{K}_2\text{CO}_3$  (5.2 g, 38.0 mmol) in dry THF (25.0 mL) under nitrogen, 3-aminopentane (3.3 mL, 2.5 g, 28.6 mmol) was added. After 4 h stirring at room temperature, THF was removed under reduced pressure, and water (100 mL) was added to the residue. The aqueous phase was extracted with ethyl acetate (3 x 100 mL). The combined organic phases were followed by washing with additional water (150 mL), drying over sodium sulfate, filtering and evaporating to yield 6.17 g (92%) of the NMR-pure product **3** as an orange oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 8.87$  (d,  $J = 2.0$  Hz, 1 H, 2- $\text{H}_{\text{Ar}}$ ), 8.34 (br. d,  $J = 7.6$  Hz, 1 H, NH), 8.00 (dd,  $J = 9.2$ , 2.0 Hz, 1 H, 6- $\text{H}_{\text{Ar}}$ ), 6.86 (d,  $J = 9.2$  Hz, 1 H, 5- $\text{H}_{\text{Ar}}$ ), 3.88 (s, 3 H,  $\text{CH}_3\text{O}$ ), 3.58–3.50 (m, 1 H, NHCH), 1.77–1.56 (m, 4 H, 2  $\text{CH}_2\text{CH}_3$ ), 0.97 (t,  $J = 7.6$  Hz, 6 H, 2  $\text{CH}_2\text{CH}_3$ ) ppm.  $^{13}\text{C}$  NMR

(100 MHz,  $\text{CDCl}_3$ ):  $\delta = 165.8$  ( $\text{CO}_2\text{CH}_3$ ), 148.0 (4- $\text{C}_{\text{Ar}}$ ), 136.3 (6- $\text{H}_{\text{Ar}}$ ), 131.2 (3- $\text{C}_{\text{Ar}}$ ), 130.0 (2- $\text{H}_{\text{Ar}}$ ), 116.8 (1- $\text{C}_{\text{Ar}}$ ), 114.0 (5- $\text{H}_{\text{Ar}}$ ), 55.8 (NHCH), 52.1 ( $\text{CO}_2\text{CH}_3$ ), 26.9 (2  $\text{CH}_2\text{CH}_3$ ), 10.2 (2  $\text{CH}_2\text{CH}_3$ ) ppm. HRMS (ESI): calcd. for  $\text{C}_{13}\text{H}_{19}\text{N}_2\text{O}_4^+$  [ $\text{M} + \text{H}^+$ ]: 267.1339; found: 267.1343.

#### 4.1.3. Methyl 3-amino-4-(pentan-3-ylamino)benzoate (4)

A solution of methyl 3-nitro-4-(pentan-3-ylamino)benzoate (**3**) (6.2 g, 23.2 mmol) in ethanol (70 mL) was hydrogenated with molecular hydrogen at 5 bar over 10% Pd/C (0.35 g, 0.33 mmol Pd) for 16 h in a Parr machine. The reaction mixture was filtered via a plug of Celite, and ethanol was removed under reduced pressure to yield an oily residue. Purification of the residue by FC on silica gel (20% ethyl acetate in hexane) afforded 4.7 g (85%) of the title product as a brownish waxy solid,  $R_f = 0.22$  (ethyl acetate/hexane, 1:4).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 7.57$  (dd,  $J = 8.4$ , 2 Hz, 1.0 H, 6- $\text{H}_{\text{Ar}}$ ), 7.41 (d,  $J = 2.0$  Hz, 1 H, 2- $\text{H}_{\text{Ar}}$ ), 6.55 (d,  $J = 8.8$  Hz, 1 H, 5- $\text{H}_{\text{Ar}}$ ), 3.84 (s, 3 H,  $\text{CH}_3\text{O}$ ), 3.32 (qui,  $J = 6.0$  Hz, 1 H, CHN), 1.68–1.48 (m, 4 H, 2  $\text{CH}_2\text{CH}_3$ ), 0.94 (t,  $J = 7.6$  Hz, 6 H, 2  $\text{CH}_2\text{CH}_3$ ) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta = 167.5$  ( $\text{CO}_2\text{CH}_3$ ), 143.2 (4- $\text{C}_{\text{Ar}}$ ), 131.5 (3- $\text{C}_{\text{Ar}}$ ), 126.6 (6- $\text{H}_{\text{Ar}}$ ), 118.9 (2- $\text{H}_{\text{Ar}}$ ), 117.7 (1- $\text{C}_{\text{Ar}}$ ), 109.3 (5- $\text{H}_{\text{Ar}}$ ), 55.1 (NHCH), 51.5 ( $\text{CO}_2\text{CH}_3$ ), 26.7 (2  $\text{CH}_2\text{CH}_3$ ), 10.1 (2  $\text{CH}_2\text{CH}_3$ ) ppm. LRMS (ESI): calcd. for  $\text{C}_{13}\text{H}_{21}\text{N}_2\text{O}_2^+$  [ $\text{M} + \text{H}^+$ ]: 237.16; found: 237.2.

#### 4.1.4. Methyl 2-(thiophen-2-yl)acetimidate Hydrochloride (6)

Acetyl chloride (8.0 mL, 8.8 g, 101.3 mmol) was added dropwise over 10 min to a cold (0 °C) well-stirred solution of 2-thiopheneacetonitrile (**5**) (3.4 mL, 4.0 g, 32.4 mmol) and dry methanol (6.6 mL, 5.2 g, 162.9 mmol) in dry diethyl ether (30 mL) under nitrogen. After the addition, the reaction mixture was stirred at 0 °C for an additional hour, then was closed well and kept in the cold (4 °C) without stirring. Colorless crystals precipitated after 3 days. The crystals were filtered via a glass sinter, washed with dry ether (60 mL), and then dried in vacuum to generate 5.44 g (87%) of a highly hygroscopic solid imidate salt **6**.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 12.90$  (br. s, 1 H,  $\text{H}_a\text{H}_b\text{N}^+$ ), 11.94 (br. s, 1 H,  $\text{H}_a\text{H}_b\text{N}^+$ ), 7.30–7.28 (m, 1 H, 5- $\text{H}_{\text{Th}}$ ), 7.20 (d,  $J = 3.6$  Hz, 1 H, 3- $\text{H}_{\text{Th}}$ ), 7.02–7.00 (m, 1 H, 4- $\text{H}_{\text{Th}}$ ), 4.33 (s, 5 H,  $\text{CH}_2 + \text{OCH}_3$ ) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta = 177.0$  ( $\text{OC}=\text{N}^+\text{H}_2$ ), 130.9 (2- $\text{C}_{\text{Th}}$ ), 129.0 (3- $\text{H}_{\text{Th}}$ ), 127.5 (4- $\text{H}_{\text{Th}}$ ), 126.5 (5- $\text{H}_{\text{Th}}$ ), 61.2 ( $\text{OCH}_3$ ), 33.2 ( $\text{CH}_2$ ) ppm.

#### 4.1.5. Methyl 1-(pentan-3-yl)-2-(thiophen-2-ylmethyl)-1H-benzod[imidazole-5-carboxylate (7)

A homogeneous solution of methyl 3-amino-4-(pentan-3-ylamino)benzoate (**4**) (3.0 g, 12.9 mmol) and methyl 2-thiopheneacetimidate hydrochloride (**6**) (2.5 g, 12.9 mmol) was refluxed in dry methanol (20.0 mL) for 8 h under nitrogen. The methanol was removed under reduced pressure, the residue was partitioned between ethyl acetate (200 mL) and water (100 mL), the organic layer was washed with additional water (2x100 mL) and brine (100 mL), and dried over sodium sulfate. Filtration, then evaporation followed by FC on silica gel (gradient elution with ethyl acetate - hexane) yielded 2.5 g (57%) of the title product **7**,  $R_f = 0.45$  (ethyl acetate - toluene, 3:7). A beige solid, m.p. 101–103 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 8.48$  (d,  $J = 1.2$  Hz, 1 H, 4- $\text{H}_{\text{BZM}}$ ), 7.92 (dd,  $J =$

8.8, 1.6 Hz, 1 H, 6-H<sub>BZM</sub>), 7.45 (d, *J* = 8.4 Hz, 1 H, 7-H<sub>BZM</sub>), 7.18 (dd, *J* = 5.2, 1.2 Hz, 1 H, 5-H<sub>Th</sub>), 6.94-6.90 (m, 2 H, 3-+4-H<sub>Th</sub>), 4.51 (s, 2 H, CH<sub>2</sub>C), 4.19-4.11 (m, 1 H, CHN), 3.94 (s, 3 H, CH<sub>3</sub>O), 2.04-1.85 (m, 4 H, 2 CH<sub>2</sub>CH<sub>3</sub>), 0.61 (t, *J* = 7.6 Hz, 6 H, 2 CH<sub>2</sub>CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ = 167.6 (CO<sub>2</sub>CH<sub>3</sub>), 155.0 (2-C<sub>BZM</sub>), 142.8 (9-C<sub>BZM</sub>), 138.3 (2-C<sub>Th</sub>), 136.8 (8-C<sub>BZM</sub>), 127.0 (4-HC<sub>Th</sub>), 126.3 (3-HC<sub>Th</sub>), 124.9 (5-HC<sub>Th</sub>), 124.0 (5-C<sub>BZM</sub>), 123.7 (6-HC<sub>BZM</sub>), 122.3 (4-HC<sub>BZM</sub>), 111.3 (7-HC<sub>BZM</sub>), 61.0 (NCH), 52.0 (CH<sub>3</sub>O), 29.7 (CH<sub>2</sub>C), 26.7 (2 CH<sub>2</sub>CH<sub>3</sub>), 10.8 (2 CH<sub>2</sub>CH<sub>3</sub>) ppm. HRMS (ESI): calcd. for C<sub>19</sub>H<sub>23</sub>N<sub>2</sub>O<sub>2</sub>S<sup>+</sup> [M + H<sup>+</sup>]: 343.1475; found: 343.1473.

#### 4.1.6. 1-(Pentan-3-yl)-2-(thiophen-2-ylmethyl)-1H-benzof[d]imidazole-5-carboxylic Acid (8)

To a solution of methyl ester **7** (200 mg, 0.6 mmol) in methanol (2.0 mL) and THF (3.0 mL), 1 M aqueous solution of sodium hydroxide (1.2 mL) was added, and the reaction mixture was stirred at room temperature overnight. The solvents were removed under reduced pressure and water (50 mL) was added. The mixture was adjusted to pH 4 by the addition of 2.0 M aqueous HCl and the aqueous phase was extracted with ethyl acetate (3 x 100 mL). The combined organic phase was followed by washing with brine (100 mL), drying over sodium sulfate, filtering, evaporating, and vacuuming to afford 170 mg (87%) of carboxylic acid **8** as a light brown solid, mp 83-86 °C. <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>): δ = 8.81 (s, 1 H, 4-H<sub>BZM</sub>), 8.05 (d, *J* = 8.4 Hz, 1 H, 6-H<sub>BZM</sub>), 7.51 (d, *J* = 8.4 Hz, 1 H, 7-H<sub>BZM</sub>), 7.18 (d, *J* = 4.9 Hz, 1 H, 5-H<sub>Th</sub>), 6.97 (d, *J* = 3.5 Hz, 1 H, 3-H<sub>Th</sub>), 6.94-6.93 (m, 1 H, 4-H<sub>Th</sub>), 4.78 (s, 2 H, CH<sub>2</sub>C), 4.25-4.20 (m, 1 H, CHN), 2.05-1.91 (m, 4 H, 2 CH<sub>2</sub>CH<sub>3</sub>), 0.64 (t, *J* = 7.0 Hz, 6 H, 2 CH<sub>2</sub>CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (175 MHz, CDCl<sub>3</sub>): δ = 170.4 (CO<sub>2</sub>H), 155.1 (2-C<sub>BZM</sub>), 141.6 (9-C<sub>BZM</sub>), 138.3 (2-C<sub>Th</sub>), 136.4 (8-C<sub>BZM</sub>), 127.3 (4-HC<sub>Th</sub>), 126.6 (3-HC<sub>Th</sub>), 125.5 (5-C<sub>BZM</sub>), 125.0 (5-HC<sub>Th</sub>), 124.6 (6-HC<sub>BZM</sub>), 122.4 (4-HC<sub>BZM</sub>), 111.7 (7-HC<sub>BZM</sub>), 61.2 (NCH), 29.1 (CH<sub>2</sub>C), 26.8 (CH<sub>2</sub>CH<sub>3</sub>), 11.0 (CH<sub>2</sub>CH<sub>3</sub>) ppm. HRMS (ESI): calcd. for C<sub>18</sub>H<sub>21</sub>N<sub>2</sub>O<sub>2</sub>S<sup>+</sup> [M + H<sup>+</sup>]: 329.1318; found: 329.1316.

#### 4.1.7. Methyl (S)-5-methyl-3-((1-(pentan-3-yl)-2-(thiophen-2-ylmethyl)-1H-benzof[d]imidazole-5-carboxamido)hexanoate (9)

To a well-stirred solution of carboxylic acid **8** (500 mg, 1.5 mmol) in dry DMF (10 mL) at 0 °C under nitrogen, HOBt (310 mg, 2.3 mmol), EDC (450 mg, 2.89 mmol), and DIEA (0.60 mL, 452 mg, 3.9 mmol) were added consecutively. After 15 min stirring at 0 °C, a solution of methyl (S)-3-amino-5-methylhexanoate (850 mg, 5.3 mmol) and DIEA (0.6 mL, 452 mg, 3.9 mmol) in dry DMF (2 mL) was added. The reaction mixture was stirred at ambient temperature for 3 days and poured into water (125 mL). The solution was acidified to pH 3 by the addition of 2.0 M aqueous HCl and extracted with ethyl acetate (2 x 250 mL). The combined organic phase was washed with saturated sodium bicarbonate (2 x 200 mL) and brine (200 mL), dried over sodium sulfate, filtered, and evaporated. Purification of the residue by FC on Florisil (20% ethyl acetate in hexane) yielded 420 mg (58%) of the title product **9** as a pale brown oil, *R*<sub>f</sub> = 0.36 (ethyl acetate/toluene, 1:1); [α]<sub>D</sub><sup>25</sup> = 23.7 (c = 0.002, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>): δ = 8.58 (s, 1 H, 4-H<sub>BZM</sub>), 8.16 (d, *J* = 8.4 Hz, 1 H, 6-H<sub>BZM</sub>), 7.17-7.13 (m, 2 H, NH + 7-H<sub>BZM</sub>), 6.78 (d, *J* = 5.2 Hz,

1 H, 5-H<sub>Th</sub>), 6.70 (d, *J* = 2.0 Hz, 1 H, 3-H<sub>Th</sub>), 6.66-6.64 (m, 1 H, 4-H<sub>Th</sub>), 4.87-4.81 (m, 1 H, CONHCH), 4.24 (s, 2 H, C<sub>BZM</sub>CH<sub>2</sub>C<sub>Th</sub>), 3.76-3.70 (m, 1 H, N<sub>BZM</sub>CH), 3.32 (s, 3 H, CH<sub>3</sub>O), 2.54-2.45 (m, 2 H, CH<sub>3</sub>O<sub>2</sub>CCH<sub>2</sub>), 1.74-1.66 (m, 1 H, CH(CH<sub>3</sub>)<sub>2</sub>), 1.63-1.54 [m, 3 H, CH<sub>a</sub>H<sub>b</sub>CH(CH<sub>3</sub>)<sub>2</sub> + CH<sub>2</sub>CH<sub>3</sub>], 1.41-1.31 (m, 2 H, CH<sub>2</sub>CH<sub>3</sub>), 1.28-1.21 [m, 1 H, CH<sub>a</sub>H<sub>b</sub>CH(CH<sub>3</sub>)<sub>2</sub>], 0.95 [d, *J* = 6.4 Hz, 3 H, CH(CH<sub>3</sub>)CH<sub>3</sub>], 0.84 [d, *J* = 6.4 Hz, 3 H, CH(CH<sub>3</sub>)CH<sub>3</sub>], 0.34 (t, *J* = 7.2 Hz, 6 H, 2 CH<sub>2</sub>CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100 MHz, C<sub>6</sub>D<sub>6</sub>): δ = 172.4 (CO<sub>2</sub>CH<sub>3</sub>), 167.0 (CONH), 154.7 (2-C<sub>BZM</sub>), 143.7 (9-C<sub>BZM</sub>), 139.3 (2-C<sub>Th</sub>), 136.0 (8-C<sub>BZM</sub>), 129.7 (5-C<sub>BZM</sub>), 127.1 (4-HC<sub>Th</sub>), 126.5 (3-HC<sub>Th</sub>), 124.9 (5-HC<sub>Th</sub>), 122.8 (6-HC<sub>BZM</sub>), 119.1 (4-HC<sub>BZM</sub>), 111.9 (7-HC<sub>BZM</sub>), 60.7 (N<sub>BZM</sub>CH), 51.2 (CH<sub>3</sub>O), 45.2 (CONHCH), 43.9 [CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>], 39.8 (CH<sub>3</sub>O<sub>2</sub>CCH<sub>2</sub>), 29.6 (C<sub>Th</sub>CH<sub>2</sub>), 26.7 (2 CH<sub>2</sub>CH<sub>3</sub>), 25.5 [CH(CH<sub>3</sub>)<sub>2</sub>], 23.3 [CH(CH<sub>3</sub>)CH<sub>3</sub>], 22.3 [CH(CH<sub>3</sub>)CH<sub>3</sub>], 10.8 (2 CH<sub>2</sub>CH<sub>3</sub>) ppm. HRMS (ESI): calcd. for C<sub>26</sub>H<sub>36</sub>N<sub>3</sub>O<sub>3</sub>S<sup>+</sup> [M + H<sup>+</sup>]: 470.2472; found: 470.2479.

#### 4.1.8. Potassium (S)-5-methyl-3-((1-(pentan-3-yl)-2-(thiophen-2-ylmethyl)-1H-benzof[d]imidazole-5-carboxamido)hexanoate - CMF-019 (potassium salt) (10)

To a solution of methyl ester **9** (50 mg, 0.1 mmol) in THF (1.0 mL) an aqueous solution of KOH (7 mg, 0.12 mmol in 0.6 mL of H<sub>2</sub>O) was added slowly at 0 °C and the reaction mixture was stirred at room temperature for 21 h. THF and water were removed under reduced pressure to afford an oily residue. The residue was treated with ethyl ether (10 mL), and the mixture was stirred for 30 min to afford a pale insoluble precipitate. The solution was decanted off the solid and discarded. The solid residue was purified using reverse phase preparative HPLC to afford, after thorough lyophilization for 5 days, 30 mg (57%) of the target CMF-019 (potassium salt) (**10**). The product is a colorless hygroscopic powder, m.p. 116-120 °C; [α]<sub>D</sub><sup>25</sup> = -16.9 (c = 0.002, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ = 9.81 (d, *J* = 8.0 Hz, 1 H, CONH), 8.02 (d, *J* = 0.8 Hz, 1 H, 4-H<sub>BZM</sub>), 7.66-7.60 (m, 2 H, 6 + 7-H<sub>BZM</sub>), 7.38 (dd, *J* = 5.2, 1.2 Hz, 1 H, 5-H<sub>Th</sub>), 7.07 (dd, *J* = 3.2, 1.2 Hz, 1 H, 3-H<sub>Th</sub>), 6.96 (dd, *J* = 5.2, 3.2 Hz, 1 H, 4-H<sub>Th</sub>), 4.54 (s, 2 H, C<sub>BZM</sub>CH<sub>2</sub>C<sub>Th</sub>), 4.35-4.27 (m, 1 H, N<sub>BZM</sub>CH), 4.18-4.10 (m, 1 H, CONHCH), 2.10 (d, *J* = 4.4 Hz, 2 H, CH<sub>3</sub>O<sub>2</sub>CCH<sub>2</sub>), 1.99-1.82 (m, 4 H, 2 CH<sub>2</sub>CH<sub>3</sub>), 1.65-1.55 [m, 1 H, CH<sub>a</sub>H<sub>b</sub>CH(CH<sub>3</sub>)<sub>2</sub>], 1.54-1.47 [m, 1 H, CH<sub>a</sub>H<sub>b</sub>CH(CH<sub>3</sub>)<sub>2</sub>], 1.35-1.28 [m, 1 H, CH<sub>a</sub>H<sub>b</sub>CH(CH<sub>3</sub>)<sub>2</sub>], 0.90 (d, *J* = 6.4 Hz, 3 H, CH(CH<sub>3</sub>)CH<sub>3</sub>), 0.86 [d, *J* = 6.4 Hz, 3 H, CH(CH<sub>3</sub>)CH<sub>3</sub>], 0.50 (t, *J* = 7.2 Hz, 6 H, 2 CH<sub>2</sub>CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>): δ = 174.3 (CO<sub>2</sub><sup>-</sup>), 164.8 (CON), 155.0 (2-C<sub>BZM</sub>), 142.4 (9-C<sub>BZM</sub>), 139.2 (2-C<sub>Th</sub>), 134.7 (8-C<sub>BZM</sub>), 129.0 (5-C<sub>BZM</sub>), 126.7 (4-HC<sub>Th</sub>), 126.4 (3-HC<sub>Th</sub>), 125.4 (5-HC<sub>Th</sub>), 120.9 (6-HC<sub>BZM</sub>), 117.7 (4-HC<sub>BZM</sub>), 111.5 (7-HC<sub>BZM</sub>), 59.5 (N<sub>BZM</sub>CH), 45.1 (CONHCH), 43.9 [CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>], 41.8 (CH<sub>2</sub>CO<sub>2</sub><sup>-</sup>), 28.5 (C<sub>Th</sub>CH<sub>2</sub>), 25.8 (2 CH<sub>2</sub>CH<sub>3</sub>), 24.8 [CH(CH<sub>3</sub>)<sub>2</sub>], 22.9 [CH(CH<sub>3</sub>)CH<sub>3</sub>], 22.7 [CH(CH<sub>3</sub>)CH<sub>3</sub>], 10.3 (2 CH<sub>2</sub>CH<sub>3</sub>) ppm. HRMS (ESI): calcd. for C<sub>25</sub>H<sub>33</sub>KN<sub>3</sub>O<sub>3</sub>S<sup>+</sup> [M + H<sup>+</sup>]: 494.1874; found: 494.1870.

## CONCLUSION

An improved, convenient synthesis of CMF-019 (potassium salt) (**10**) was developed and reported here with detailed synthetic procedures and spectroscopic data. The

elaborated synthesis avoids the use of high-pressure hydrogenation and a dedicated microwave reactor. Since **10** is a potent APJ receptor agonist, a description of its expedient synthesis could benefit investigating the apelin-APJ system and potential treatment of the system's dysfunction-associated disorders.

## ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

## HUMAN AND ANIMAL RIGHTS

No Animals/Humans were used for studies that are the basis of this research.

## CONSENT FOR PUBLICATION

Not applicable.

## CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

## ACKNOWLEDGEMENTS

We thank Gila Levy for her assistance with the polarimetric measurements and Steve Manch for English editing. This study was supported by a Bar-Ilan University new faculty grant (AG), by the Israel Ministry of Immigration and Integration through Kamea fellowship (EEK), and by EY024864 and EY027283 grants (KP).

## SUPPLEMENTARY MATERIAL

Supplementary material is available on the publisher's web site along with the published article.

## REFERENCES

- [1] O'Dowd, B.F.; Heiber, M.; Chan, A.; Heng, H.H.; Tsui, L.C.; Kennedy, J.L.; Shi, X.; Petronis, A.; George, S.R.; Nguyen, T. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. *Gene*, **1993**, *136*, 355-360.
- [2] Tatemoto, K.; Hosoya, M.; Habata, Y.; Fujii, R.; Kakegawa, T.; Zou, M.X.; Kawamata, Y.; Fukusumi, S.; Hinuma, S.; Kitada, C.; Kurokawa, T.; Onda, H.; Fujino, M. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. *Biochem. Biophys. Res. Commun.*, **1998**, *251*, 471-476.
- [3] Japp, A.G.; Newby, D.E. The apelin-APJ system in heart failure pathophysiologic relevance and therapeutic potential. *Biochem. Pharmacol.*, **2008**, *75*, 1882-1892.
- [4] Narayanan, S.; Harris, D.L.; Maitra, R.; Runyon, S.P. Regulation of the apelinergic system and its potential in cardiovascular disease: peptides and small molecules as tools for discovery. *J. Med. Chem.*, **2015**, *58*, 7913-7927.
- [5] Japp, A.G.; Cruden, N.L.; Amer, D.A.; Li, V.K.; Goudie, E.B.; Johnston, N.R.; Sharma, S.; Neilson, I.; Webb, D.J.; Megson, I.L.; Flapan, A.D.; Newby, D.E. Vascular effect of apelin in vivo in man. *J. Am. Coll. Cardiol.*, **2008**, *52*, 908-913.
- [6] Brame, A.L.; Maguire, J.J.; Yang, P.; Dyson, A.; Torella, R.; Cheriyan, J.; Singer, M.; Glen, R.C.; Wilkinson, I.B.; Davenport, A.P. Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. *Hypertension*, **2015**, *65*, 834-840.
- [7] Murza, A.; Parent, A.; Besserer-Offroy, E.; Tremblay, H.; Karadereye, F.; Beaudet, N.; Leduc, R.; Sarret, P.; Marsault, E. Elucidation of the structure-activity relationships of apelin: influence of unnatural amino acids on binding, signaling, and plasma stability. *ChemMedChem*, **2012**, *7*, 318-325.
- [8] a) Agyei, D.; Ahmed, I.; Akram, Z.; Iqbal, H.M.N.; Danquah, M.K. Protein and peptide biopharmaceuticals: An Overview. *Protein Peptide Lett.*, **2017**, *24*, 94-101; b) D'Addio, S.M.; Bothe, J.R.; Neri, C.; Walsh, P.L.; Zhang, J.; Pierson, E.; Mao, Y.; Gindy, M.; Leone, A.; Templeton, A.C. New and evolving techniques for the characterization of peptide therapeutics. *J. Pharm. Sci.*, **2016**, *105*, 2989-3006; c) Xiao, Y.-F.; Jie, M.-M.; Li, B.-S.; Hu, C.-J.; Xie, R.; Tang, B.; Yang, S.-M. Peptide-based treatment: a promising cancer therapy. *J. Immunol. Res.*, **2015**, *2015*, 761820; d) Khafagy, E.-S.; Morishita, M. Oral biodrug delivery using cell-penetrating peptide. *Adv. Drug Deliv. Rev.*, **2012**, *64*, 531-539.
- [9] a) Qvit, N.; Rubin, S.J.S.; Urban, T.J.; Mochly-Rosen, D.; Gross, E.R. Peptidomimetic therapeutics: scientific approaches and opportunities. *Drug Discov. Today*, **2017**, *22*, 454-462; b) Royo Gracia, S.; Gaus, K.; Sewald, N. Synthesis of chemically modified bioactive peptides: recent advances, challenges and developments for medicinal chemistry. *Future Med. Chem.*, **2009**, *1*, 1289-1310; c) Fabbri, P.; Menchi, G.; Guarna, A.; Trabocchi, A. Use of click-chemistry in the development of peptidomimetic enzyme inhibitors. *Curr. Med. Chem.*, **2014**, *21*, 1467-1477.
- [10] a) Hachtel, S.; Wohlfart, P.; Weston, J.; Mueller, M.; Defossa, E.; Mertsch, K.; Weng, J.-H.; Binnie, R.A.; Abdul-Latif, F.; Bock, W.J.; Walser, A. Preparation of benzimidazolecarboxylic acid amino acid amides as apelin receptor modulators. WO2014,044738 A1, March 27, **2014**; b) Hachtel, S.; Wohlfart, P.; Weston, J.; Mueller, M.; Defossa, E.; Mertsch, K.; Weng, J.-H.; Binnie, R.A.; Abdul-Latif, F.; Bock, W.J.; Walser, A. Benzoimidazolecarboxylic acid amide derivatives as APJ receptor modulators. U.S. Patent 2014,0094450 A1, April 3, **2014**.
- [11] Read, C.; Fitzpatrick, C.M.; Yang, P.; Kuc, R.E.; Maguire, J.J.; Glen, R.C.; Foster, R.E.; Davenport, A.P. Cardiac action of the first G protein biased small molecule apelin agonist. *Biochem. Pharmacol.*, **2016**, *116*, 63-72.
- [12] Dietrich, S.A.; Lindauer, R.; Stierlin, C.; Gertsch, J.; Matesanz, R.; Notararigo, S.; Fernando, D.; Altmann, K.H. Epothilone analogues with benzimidazole and quinoline side chains: chemical synthesis, antiproliferative activity, and interactions with tubulin. *Chem. Eur. J.*, **2009**, *15*, 10144-10157.
- [13] For a brief discussion on efficiency and reproducibility of microwave-assisted reactions, see, e.g.: a) Lidström, P.; Tierney, J.; Wathey, B.; Westman, J. Microwave assisted organic synthesis – a review. *Tetrahedron*, **2001**, *57*, 9225-9283; b) Kappe, C.O. Controlled microwave heating in modern organic synthesis. *Angew. Chem., Int. Ed.*, **2004**, *43*, 6250-6284; c) Gising, J.; Odell, L.R.; Larhed, M. Microwave-assisted synthesis of small molecules targeting the infectious diseases tuberculosis, HIV/AIDS, malaria and hepatitis C. *Org. Biomol. Chem.*, **2012**, *10*, 2713-2729; d) Bana, P.; Greiner, B. Comparison of conventional and microwave heating for evaluation of microwave effects. *Austral. J. Chem.*, **2016**, *69*, 865-871.
- [14] The imidate hydrochloride **6** was previously prepared according to the standard Pinner method and reported without spectral characterization. See: Leschke, C.; Elz, S.; Garbag, M.; Schunack, W. Synthesis and histamine H<sub>1</sub> receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues. *J. Med. Chem.*, **1995**, *38*, 1287-1294.
- [15] For selected recent reviews on synthesis of benzimidazoles, see: a) Grimmett, M.R. Product class 4: benzimidazoles. In: *Science of Synthesis*; Neier, R., Ed.; Georg Thieme: New York, **2002**, Vol. 12, pp. 529-612; b) Carvalho, L.C.R.; Fernandes, E.; Marques, M.M.B. Developments towards regioselective synthesis of 1,2-disubstituted benzimidazoles. *Chem. Eur. J.*, **2011**, *17*, 12544-12555; c) Arulmugan, S.; Kavitha, H.P.; Sathishkumar, S.; Arumozhi, R. Biologically active benzimidazole derivatives. *Mini-Rev. Org. Chem.*, **2015**, *12*, 178-195; d) Rajasekhara, S.; Mati, B.; Balamurali, M.M.; Chanda, K. Synthesis and medicinal applications of benzimidazoles: an overview. *Curr. Org. Synth.*, **2017**, *14*, 40-60.
- [16] a) King, F.E.; Acheson, R.M. Synthesis of benzimidazoles from o-phenylenediamines and imino ethers. *J. Chem. Soc.*, **1949**, 1396-1400; b) Chapman, D.D.; Elwood, J.K.; Heseltine, D.W.; Hess, H.M.; Kurtz, D.W. Annelation of pyridinium rings onto nitrogen

- heterocycles. *J. Org. Chem.*, **1977**, 42, 2474-2480; c) Musser, J.H.; Kubrak, D.M.; Chang, J.; DiZio, S.M.; Hite, M.; Hand, J.M.; Lewis, A.J. Leukotriene D<sub>4</sub> antagonists and 5-lipoxygenase inhibitors. Synthesis of benzoheterocyclic [(methoxyphenyl)amino] oxoalkanoic acid esters. *J. Med. Chem.*, **1987**, 30, 400-405; d) Caron, S.; Jones, B.P.; Wei, L. Preparation of substituted benzimidazoles and imidazopyridines using 2,2,2-trichloroethyl imidates. *Synthesis*, **2012**, 3049-3054; e) Bandarage, U.; Hare, B.; Parsons, J.; Pham, L.; Marhefka, C.; Bemis, G.; Tang, Q.; Moody, C.S.; Rodems, S.; Shah, S.; Adams, C.; Bravo, J.; Charonnet, E.; Savic, V.; Come, J.H.; Green, J. 4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Potent and selective p70S6 kinase inhibitors. *Bioorg. Med. Chem. Lett.*, **2009**, 19, 5191-5194; f) Burgeson, J.R.; Moore, A.L.; Gharaibeh, D.N.; Larson, R.A.; Cerruti, N.R.; Amberg, S.M.; Hruby, D.E.; Dai, D. Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole and related heterocycles. *Bioorg. Med. Chem. Lett.*, **2013**, 23, 750-756; g) Tonelli, M.; Novelli, F.; Tasso, B.; Vazzana, I.; Sparatore, A.; Boido, V.; Sparatore, F.; La Colla, P.; Sanna, G.; Giliberti, G.; Busonera, B.; Farci, P.; Ibba, C.; Loddo, R. Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents. *Bioorg. Med. Chem.*, **2014**, 22, 4893-4909.
- [17] For the originally reported "modified Pinner method", consisting of reaction of nitrile with excess alcohol and acetyl chloride as HCl-source without an inert diluting solvent, see: a) Yadav, V.K.; Babu, K.G. A remarkably efficient Markovnikov hydrochlorination of olefins and transformation of nitriles into imidates by use of AcCl and an alcohol. *Eur. J. Org. Chem.*, **2005**, 2005, 452-456; b) Kumar, Y.; Shaw, M.; Thakur, R.; Kumar, A. Copper(II)-mediated aerobic oxidation of benzylimidates: Synthesis of primary  $\alpha$ -ketoamides. *J. Org. Chem.*, **2016**, 81, 6617-6625.
- [18] Reactions of imidates and their salts with anilines represent a classical synthesis of N-arylamidines. For a review, see: a) Dunn, P.J. In *Comprehensive Organic Functional Group Transformations II*; Elsevier: Oxford, UK, **2005**; Vol. 5, pp. 655-699. For selected more recent examples, see: b) Caron, S.; Wei, L.; Douville, J.; Ghosh, A. Preparation and utility of trihaloethyl imidates: useful reagents for the synthesis of amidines. *J. Org. Chem.*, **2010**, 75, 945-947; c) Causey, C.P.; Jones, J.E.; Slack, J.L.; Kamei, D.; Jones, Jr., L.E.; Subramanian, V.; Knuckley, B.; Ebrahimi, P.; Chumanovich, A.A.; Luo, Y.; Hashimoto, H.; Sato, M.; Hofseth, L.J.; Thompson, P.R. The development of N- $\alpha$ -(2-carboxyl)benzoyl-N<sup>5</sup>-(2-fluoro-1-iminoethyl)-L-ornithine amide (o-F-amidine) and N- $\alpha$ -(2-carboxyl)benzoyl-N<sup>5</sup>-(2-chloro-1-iminoethyl)-L-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors. *J. Med. Chem.*, **2011**, 54, 6919-6935; d) Annedi, S.C.; Maddaford, S.P.; Ramnauth, J.; Renton, P.; Speed, J.; Rakhit, S.; Andrews, J.S.; Porreca, F. 3,5-Disubstituted indole derivatives as selective human neuronal nitric oxide synthase (nNOS) inhibitors. *Bioorg. Med. Chem. Lett.*, **2012**, 22, 1980-1984; e) Weigel, L.F.; Nitsche, C.; Graf, D.; Bartenschlager, R.; Klein, C.D. Phenylalanine and phenylglycine analogues as arginine mimetics in dengue protease inhibitors. *J. Med. Chem.*, **2015**, 58, 7719-7733.
- [19] Intentionally prepared or unambiguously generated N-(*ortho*-aminophenyl)amidines are spontaneously cyclised to benzimidazoles even at ambient temperature. See: a) Hölljes, Jr., E.L.; Wagner, E.C. Some reactions of nitriles as acid anammonides. *J. Org. Chem.*, **1944**, 9, 31-49; b) Gupta, S.; Agarwal, P.K.; Kundu, B. Catalyst/ligand-free synthesis of benzimidazoles and quinazolinones from amidines via intramolecular transamination reaction. *Tetrahedron Lett.*, **2010**, 51, 1887-1890.
- [20] Enantiopure methyl (*S*)-3-amino-5-methylhexanoate,  $[\alpha]_D^{25} = +2.4$  ( $c = 0.002$ , CHCl<sub>3</sub>), was purchased from Aquila Pharmatech LLC (USA).
- [21] Bennet, C.E. Potassium tremethylsilanolate. In: *e-EROS Encyclopedia of Reagents for Organic Synthesis*; Wiley: Chichester, **2009**, pp. 1-2.
- [22] Gottlieb, H.E.; Kotlyar, V.; Nudelman, A. NMR chemical shifts of common laboratory solvents as trace impurities. *J. Org. Chem.*, **1997**, 62, 7512-7515.

## Supplementary Material

### **An Expedient Synthesis of CMF-019: (S)-5-Methyl-3-{1-(pentan-3-yl)-2-(thiophen-2-ylmethyl)-1*H*-benzo[d]imidazole-5-carboxamido}hexanoic Acid, a Potent Apelin Receptor (APJ) Agonist**

Lena Trifonov<sup>1</sup>, Michal Afri<sup>1</sup>, Krzysztof Palczewski<sup>2</sup>, Edward E. Korshin<sup>1,\*</sup> and Arie Gruzman<sup>1,\*</sup>

<sup>1</sup>Department of Chemistry, Bar-Ilan University, Ramat-Gan, 5290002, Israel; <sup>2</sup>Department of Pharmacology, School of Medicine, Case Western Reserve University, Cleveland, OH, 44106-4965, USA





**Contents**



1. NMR spectra images.....	2
2. Mass spectroscopy data.....	16
3. Chiral HPLC report (methyl (S)-3-amino-5-methylhexanoate).....	22

## 1. NMR spectra images



<sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>)





<sup>13</sup>C-NMR (100MHz, CDCl<sub>3</sub>)





<sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>)





<sup>13</sup>C-NMR (100MHz, CDCl<sub>3</sub>)





<sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>)



<sup>13</sup>C-NMR (100MHz, CDCl<sub>3</sub>)




<sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>)









<sup>13</sup>C-NMR (100MHz, CDCl<sub>3</sub>)





<sup>1</sup>H-NMR (700MHz, CDCl<sub>3</sub>)






<sup>13</sup>C-NMR (175MHz, CDCl<sub>3</sub>)





<sup>1</sup>H-NMR (400MHz, C<sub>6</sub>D<sub>6</sub>)






<sup>1</sup>H-NMR (400MHz, DMSO)


<sup>13</sup>C-NMR (100MHz, DMSO)



## 2. Mass Spectrometry analytical data




MS Spectrum



MS Spectrum Peak List


m/z	Calc m/z	Diff(ppm)	z	Abund	Formula	Ion
267.13433	267.13393	-1.5	1	64685.58	C <sub>13</sub> H <sub>18</sub> N <sub>2</sub> O <sub>4</sub>	(M+H)+
268.1375	268.13703	-1.74	1	9762.74	C <sub>13</sub> H <sub>18</sub> N <sub>2</sub> O <sub>4</sub>	(M+H)+
269.13861	269.13927	2.47	1	936.54	C <sub>13</sub> H <sub>18</sub> N <sub>2</sub> O <sub>4</sub>	(M+H)+
289.11546	289.11588	1.43	1	1426.28	C <sub>13</sub> H <sub>18</sub> N <sub>2</sub> O <sub>4</sub>	(M+Na)+
290.12323	290.11898	-14.64	1	172.7	C <sub>13</sub> H <sub>18</sub> N <sub>2</sub> O <sub>4</sub>	(M+Na)+
305.08121	305.08962	28.19	1	5746.02	C <sub>13</sub> H <sub>18</sub> N <sub>2</sub> O <sub>4</sub>	(M+K)+
306.08348	306.09291	30.82	1	869.02	C <sub>13</sub> H <sub>18</sub> N <sub>2</sub> O <sub>4</sub>	(M+K)+
555.23952	555.24254	5.43	1	267.42	C <sub>13</sub> H <sub>18</sub> N <sub>2</sub> O <sub>4</sub>	(2M+Na)+
556.23884	556.24563	12.22	1	44.17	C <sub>13</sub> H <sub>18</sub> N <sub>2</sub> O <sub>4</sub>	(2M+Na)+






bareket LT105 170629112152 #3 RT: 0.08 AV: 1 NL: 5.82E6  
T: FTMS + c NSI Full ms [50.00-2000.00]

## Full MS




## Peak




NL:  
3.71E6  
bareket LT105 17062  
9112152#3 RT: 0.08  
AV: 1 T: FTMS + c NSI  
Full ms  
[50.00-2000.00]



## Theoretical peak




NL:  
7.62E5  
C<sub>19</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub>S +H:  
C<sub>19</sub>H<sub>23</sub>N<sub>2</sub>O<sub>2</sub>S 1  
pa Chrg 1




bareket\_LT106\_170702092508 #4 RT: 0.19 AV: 1 NL: 3.82E8  
T: FTMS + c NSI Full ms [50.00-2000.00]






NL:  
3.82E8  
bareket\_LT106\_17070  
2092508#4 RT: 0.19  
AV: 1 T: FTMS + c NSI  
Full ms  
[50.00-2000.00]




NL:  
7.71E5  
C<sub>18</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>S +H:  
C<sub>18</sub>H<sub>21</sub>N<sub>2</sub>O<sub>2</sub>S:  
pa Chrg 1




bareket\_LT108 #11 RT: 0.38 AV: 1 NL: 1.77E5  
T: FTMS + p NSI Full ms [50.00-1500.00]







bareket LT109\_170702092508 #32 RT: 1.91 AV: 1 NL: 1.25E7  
T: FTMS + c NSI Full ms [50.00-2000.00]



bareket LT109\_170702092508 #32 RT: 1.91 AV: 1 NL: 9.33E6  
T: FTMS + c NSI Full ms [50.00-2000.00]






### **3. Chiral HPLC report (methyl (S)-3-amino-5-methylhexanoate)**


(S)-3-Boc-amino-5-Methyl hexanoic acid (HB108B)  
 (This is the chiral starting material used for this product.)

## Chiral Hplc Report



## Sample Information

Lot Number: HB108B+HB109B  
 Data File: HB108B+HB109B.lcd  
 Method File: 20-80-0.5-25-OJ-RH.lcm  
 Injection Time: 2016-9-21 12:49:21  
 Report Created: 2016-9-21 13:14:25  
 Sample Info: Column: CHIRALPAK OJ-RH (150\*4.6mm 5um)  
 Mobile Phase: H2O:ACN:FA=80:20:0.1  
 Flow: 0.5 ml/min  
 Temperature: 25 C  
 Wavelength: 214nm  
 Instrument: SHIMADZU 10A  
 Inj. Volume: 20 ul



## PeakTable

PDA Ch1 214nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	15.865	4715939	76999	56.168	61.729
2	18.224	3680256	47737	43.832	38.271
Total		8396195	124737	100.000	100.000


## PeakTable

PDA Ch1 214nm 4nm

Peak#	Ret. Time	Resolution	Tailing Factor
1	15.865	0.000	2.327
2	18.224	1.163	2.215
Total			

## Spectrum


Peak# : 1  
 Retention Time : 15.865



HB109B + HB108B (R+S)  
 (R-) (S-)


The chiral HPLC report for (S)-3-Boc-amino-5-methylhexanoic acid.

# Chiral Hplc Report



## Sample Information

Lot Number: HB108B  
 Data File: HB108B.lcd  
 Method File: 20-80-0.5-25-OJ-RH.lcm  
 Injection Time: 2016-9-21 13:15:02  
 Report Created: 2016-9-21 13:40:13  
 Sample Info: Column: CHIRALPAK OJ-RH (150\*4.6mm 5um)  
 Mobile Phase: H2O:ACN:FA=80:20:0.1  
 Flow: 0.5 ml/min  
 Temperature: 25 C  
 Wavelength: 214nm  
 Instrument: SHIMADZU 10A  
 Inj. Volume: 20 ul



## PeakTable

PDA Ch1 214nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	15.291	10358966	118676	100.000	100.000
Total		10358966	118676	100.000	100.000

## PeakTable


PDA Ch1 214nm 4nm

Peak#	Ret. Time	Resolution	Separation	Tailing Factor
1	15.291	0.000	0.000	3.356
Total				

oretical Plates/me  
 3378.736

## Spectrum

Peak# : 1  
 Retention Time : 15.291





Peak# : 2  
Retention Time : 18.224

